TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06653439

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided Subcostal Quadratus Lumborum Block
Description: Bilateral ultrasound guided Subcostal Quadratus Lumborum Block (total of 40 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients in this group will not be performed plane blocks. Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine PCA
Description: IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine PCA
Description: IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
Study: NCT05598502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA, Resuscitative Endovascular Occlusion of the Aorta
Description: The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National guidelines
Description: Standard management of postpartum hemorrhage according to Uganda national guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National guidelines
Description: Standard management of postpartum hemorrhage according to Uganda national guidelines
Study: NCT06210126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic injection
Description: Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
Study: NCT05309356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
Study: NCT06210126

Intervention type: OTHER
Group type: OTHER
Intervention: Standard perioperative and postoperative analgesia protocol
Description: postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
Study: NCT06592248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coc Knee
Description: Implementation of a ceramic on ceramic knee prosthesis
Study: NCT06658912

Intervention type: OTHER
Group type: OTHER
Intervention: TOPS Classes
Description: Attend Dietician-Led Sessions
Study: NCT05371132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05614843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy density photobiomodulation (7.5)
Description: A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham placebo
Description: A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
Study: NCT05229848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D electroanatomical mapping alone guided CTI ablation
Description: 3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE plus 3D electroanatomical mapping guided CTI ablation
Description: ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
Study: NCT05618054

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Looming task
Description: Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
Study: NCT05371132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89-Df-Crefmirlimab
Description: Given IV
Study: NCT06144359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific MRI Acquisition (Diffusion Tensor Imaging) at 3T
Description: The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific MRI Acquisition (Diffusion Tensor Imaging) at 3T
Description: The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation.
Study: NCT04960475

Intervention type: OTHER
Intervention: Hospital Anxious and Depression(HADS)
Description: The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.

Intervention type: OTHER
Intervention: Hospital Anxious and Depression(HADS)
Description: The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.

Intervention type: OTHER
Intervention: Fear-Avoidance Belief Questionnaire (FABQ)
Description: FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
Study: NCT05371132

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT for Lymphoma patients only
Study: NCT06290128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:SC Injection
Study: NCT05867927

Intervention type: DEVICE
Intervention: Robotic-assisted surgery (da Vinci)
Description: Robotic-assisted surgery (da Vinci)
Study: NCT04960475

Intervention type: OTHER
Intervention: Fear-Avoidance Belief Questionnaire (FABQ)
Description: FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
Study: NCT05867927

Intervention type: DEVICE
Intervention: Non-da Vinci Surgery
Description: Non-da Vinci Surgery
Study: NCT06670326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
Study: NCT06670612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature based music concert
Description: It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
Study: NCT06670443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
Study: NCT06668935

Intervention type: DEVICE
Intervention: To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Description: All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
Study: NCT06669234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-F1202
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered per the protocol
Study: NCT06669299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-Do ventricular tachycardia ablation
Description: 1. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)
Description: The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
Study: NCT05868629

Intervention type: OTHER
Intervention: Non-investigational
Description: Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
Study: NCT06595108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
Study: NCT04707768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mircera®
Description: intravenous administration
Study: NCT06445725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Coping (ABaCo)
Description: The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
Study: NCT06669403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT101
Description: OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
Study: NCT06669728

Intervention type: DIAGNOSTIC_TEST
Intervention: AI diagnostic algorithm
Description: The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
Study: NCT05669378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite to Play +
Description: In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Appetite to Play +
Description: In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
Study: NCT05442515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
Study: NCT05962333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-arterial delivery of autologous MABs
Description: three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval